Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Not yet recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 55Carcinoma, Hepatocellular 54Lung Neoplasms 32Small Cell Lung Carcinoma 28Neoplasms 25Breast Neoplasms 20Colorectal Neoplasms 18Melanoma 15Urinary Bladder Neoplasms 13Triple Negative Breast Neoplasms 13Carcinoma, Transitional Cell 13Neoplasm Metastasis 12Carcinoma, Renal Cell 12Squamous Cell Carcinoma of Head and Neck 10Prostatic Neoplasms 9Uterine Cervical Neoplasms 8Glioblastoma 8Stomach Neoplasms 7Endometrial Neoplasms 7Ovarian Neoplasms 6Head and Neck Neoplasms 6Sarcoma 5Pancreatic Neoplasms 5Carcinoma, Neuroendocrine 5Carcinoma, Merkel Cell 5Liver Neoplasms 4Kidney Neoplasms 4Extensive Stage Lung Small Cell Carcinoma 4Carcinoma 4Brain Neoplasms 4

Interventions

pembrolizumab 2sacituzumab govitecan 1enzalutamide 1atezolizumab 1abiraterone 1Penfluridol 1PT-100 dipeptide 1PM 01183 1Nivolumab 1Ipilimumab 1Etoposide 1EC regimen 1Carboplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Small Cell × atezolizumab × 1 year × Clear all
NCT07625644 2026-06-04

Evaluate BL-M14D1 Plus Atezolizumab vs Standard of Care in First-Line Extensive-Stage Small Cell Lung Cancer

SystImmune Inc.

Phase 3 Not yet recruiting
550 enrolled
Thoracic

Lung Neoplasms, Carcinoma, Small Cell, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡